Caffeine/Ergotamine Tartrate

咖啡因/酒石酸麦角胺

Report date: 2026/03/19 20:00:18

Base Information

Drug NameCaffeine/Ergotamine Tartrate
Drug Alias Name咖啡因酒石酸麦角胺Ergotamine Tartrate and CaffeineCaffeine and Ergotamine Tartrate酒石酸麦角胺咖啡因Caffeine • Ergotamine Tartrate +[9] 
ClassificationSmall molecules
Mechanisms of ActionAdenosine A1 receptor antagonistsDopamine D2 receptor agonistsAdenosine A2a receptor antagonists +[5] 
TargetsAdrenergic receptors alpha-1Serotonin (5-HT) receptorDopamine D2 receptor +[5] 
Therapy Area/IndicationsTension-Type HeadacheMigraine DisordersVascular Headaches
Global Approved IndicationsTension-Type HeadacheMigraine DisordersVascular Headaches
Approved Indications in ChinaMigraine Disorders
Original Approved Country/TerritoryUnited States
Original Approved Date1948/11/26
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsYes CaffeineErgotamine Tartrate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNichi-Iko Pharmaceutical Co LtdTianjin Medical University Pharmaceutical Factory
Inactive CompaniesNovartis Pharma Ag
Active IndicationsTension-Type HeadacheMigraine DisordersVascular Headaches
Inactive IndicationsN/A

Other Information

ATC CodeN02CA52
Related LinksWikipediaKEGG